This is a promising sign of our ongoing work, utilizing DEXs to bind with short peptides of liver cancer-specific AFP and GPC3 that can more specifically activate T lymphocytes for prevention or targeted therapy of liver cancer. Here, GPC3 is linked to liver cancer.